Asthma just got a little easier to treat for over 20 million people in the United States. Glaxo Smith Kline (GSK) recently launched two new categories of inhalers for asthma control (and one of them for COPD). Up to now, there were only a couple of steroid containing inhalers approved for once daily use, to control asthma (Pulmicort and Asmanex). Arnuity Ellipta is now available for age 12 and older, for once daily asthma control. Breo Ellipta is a controller inhaler (inhaled steroid and long acting opening agent), and the first once daily combination inhaler approved for controlling asthma in those 18 years or older.